Reuters logo
BRIEF-Genentech says a study of co's Lampalizumab did not meet primary endpoint​
2017年9月8日 / 下午3点39分 / 3 个月前

BRIEF-Genentech says a study of co's Lampalizumab did not meet primary endpoint​

Sept 8 (Reuters) - Genentech:

* Genentech provides update on first Lampalizumab phase III study for geographic atrophy, an advanced form of age-related macular degeneration

* Spectri study did not meet its primary endpoint​

* In trial, ‍safety profile was in line with previous Lampalizumab trials and other intravitreal therapies ​

* Safety profile of patients was in line with previous Lampalizumab trials and other intravitreal therapies ​

* Results from second phase III study, Chroma, are expected in November 2017​

* Lampalizumab did not reduce mean change in GA lesion area compared to sham treatment at one year (48 weeks)​

* Given lack of efficacy, further dosing in patients will be interrupted until results from second phase III study are evaluated​ Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below